Briacell Therapeutics Corp
NASDAQ:BCTX
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
View on Canadian Exchange

  • LAST PRICE
    0.5698
  • TODAY'S CHANGE (%)
    -0.0252 (-4.2353%)
  • Bid / Lots
    0.5698/ 18
  • Ask / Lots
    0.5716/ 3
  • Open / Previous Close
    0.5884 / 0.5950
  • Day Range
    0.5550
    0.5884
  • 52 Week Range
    0.4641
    5.9700
  • Volume
    241,900

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
BCTX
Briacell Therapeutics Corp
29.4M
0.0x
---
As of 2024-11-19

Company Information

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Contact Information

Headquarters
Suite 300 - Bellevue Centre 235 -15th StreetWEST VANCOUVER, BC, Canada V7T 2X1
Phone
604-921-1810
Fax
604-921-1898

Executives

No data available

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$29.4M
Revenue (TTM)
$0.00
Shares Outstanding
35.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.80
EPS
$-0.43
Book Value
$-0.18
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.